The latest News Headlines from the Scientific, Research and HighTech world

Články z PhysOrgDrug with unique disruption of tumor blood flow shows promise

13. 1 2010 (09:00)

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).